Tech Company Financing Transactions
United Immunity Funding Round
Itochu Corporation, Miyako Capital and Mizuho Bank invested in a $13.9 million funding round for United Immunity. The funding round was recorded on 9/24/2026.
Transaction Overview
Company Name
Announced On
9/24/2026
Transaction Type
Venture Equity
Amount
$13,900,000
Round
Undisclosed
Proceeds Purpose
The company intends to use the funds to accelerate R&D of its lead program UI-102 and in vivo macrophage engineering programs for the treatment of solid tumors and fibrotic diseases, as well as to expand R&D capabilities globally.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
8th floor, 1-12-3 Nihonbashi-Muromachi, Chuo-ku
Tokyo, 103-0022
Japan
Tokyo, 103-0022
Japan
Phone
Undisclosed
Website
Email Address
Overview
United Immunity is developing next-generation in vivo cell therapies that use its proprietary Myeloid Targeting Platform� to selectively target disease-associated macrophages and dendritic cells, directly within the body and program them toward therapeutic functions.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Masato Kishida
Chief Medical Officer
Kenji Hashimoto
Chief Operating Officer
Yukiko Fujita
Chief Scientific Officer
Takatoshi Soga
Chief Technical Officer
Naozumi Harada
VP - Bus. Development
Luc St-Onge
Browse more venture capital transactions:
Prev: 9/24/2026: Trebellar venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to document every notable VC transaction. All VC database entries reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs